Published in Vaccine Weekly, November 30th, 2005
For the quarter ended September 30, 2005, Avant reported a net loss of $4.5 million, or $.06 per share, compared to a net loss of $3.7 million, or $.05 per share, for the third quarter of 2004. Avant reported cash and cash equivalents of $22 million at September 30, 2005.
Revenues during the third quarter of 2005 were $846,322 compared to revenues of $527,510 for the same period last year. Total operating expenses for the quarter were $5.5 million compared to $4.3 million in the same...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly